Molecular rearrangements in papillary thyroid carcinomas

Zitzelsberger, Horst; Bauer, Verena; Thomas, Gerry; Unger, Kristian

doi:10.1016/j.cca.2009.11.028

Cited by 18 publications

(14 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, we assessed the relationship between FOSL-2 and clinicopathological characteristics of PTC. The main results of this study are summarized as follows [1]; The genotype frequencies of promoter SNP ( rs925255 ) in FOSL-2 were significantly associated with PTC [2]. The frequency of major allele G in rs925255 was significantly higher in PTC.…”

Section: Discussionmentioning

confidence: 99%

“…It is the most common genetic alteration (average 40%) in PTC, plays an important role in carcinogenesis and disease prognosis. The next thing, RET/PTC (rearranged in transformation papillary, rearranged during transformation), Galectin-3 and NTRK 1 (neurotrophic receptor-tyrosine kinase) are well known studied at this time [2,13]. …”

Section: Discussionmentioning

confidence: 99%

“…Recently, its incidence is an explosive increase. In US, approximately 19,500 new patients of thyroid carcinoma (1% of all new case of cancer) are diagnosed each year [2]. The papillary thyroid cancer (PTC) is most common type, approximately 70% to 80% of differentiated thyroid cancer (DTC).…”

Section: Introductionmentioning

confidence: 99%

“…The papillary thyroid cancer (PTC) is most common type, approximately 70% to 80% of differentiated thyroid cancer (DTC). Most of the DTC has a good prognosis but diffuse sclerosing, tall and columnar cell variants have more aggressive clinical course [2]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association Study of FOS-Like Antigen-2 Promoter Polymorphisms With Papillary Thyroid Cancer in Korean Population

Kim

Chung

et al. 2014

Clin Exp Otorhinolaryngol

View full text Add to dashboard Cite

ObjectivesFOS-like antigen-2 (FOSL-2), a member of the FOS gene family, encode leucine zipper proteins that can heterodimerize with proteins of Jun family. Thus, activating protein (AP)-1 transcription factor is formed, has a crucial role in proliferation, differentiation and apoptosis of normal tissue as well as oncogenic transformation and progression. We performed an association study of single nucleotide polymorphisms (SNPs) in the FOSL-2 with papillary thyroid cancer (PTC). We also estimated the relationships between the SNPs and the clinicopathologic characteristics of PTC.MethodsOne promoter SNPs (rs925255) of FOSL-2 gene were genotyped with direct sequencing method in 94 PTC and 213 controls. PTC patients were dichotomized and compared with respect to clinical parameters of PTC. Genetic data were analyzed using Helixtree, SNPAnalyzer, SNPStats. Multivariate logistic regression analysis was fulfilled to evaluate the genetic effect with adjustment for age and sex.ResultsSNP (rs925255) in FOSL-2 showed a significant association (codominant 1 model [G/G vs. A/G]: odds ratio [OR], 0.531, 95% confidence interval [CI], 0.293 to 0.96, P=0.036; dominant model: OR, 0.50, 95% CI, 0.28 to 0.89, P=0.015) with PTC. The frequency of allele G in rs925255 was also significantly associated with PTC (OR, 0.59; 95% CI, 0.34 to 0.91; P=0.02). But we fail to prove significant association between this polymorphism (rs925255) and clinico-pathological parameters.ConclusionOur findings suggest that the rs925255 SNP and its allele G show significant association with the PTC in Korean population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association Study of FOS-Like Antigen-2 Promoter Polymorphisms With Papillary Thyroid Cancer in Korean Population

Kim

Chung

et al. 2014

Clin Exp Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…128–130 An oncogenic NTRK1 fusion was first detected in a colorectal cancer specimen, later found to be prevalent in papillary thyroid cancers, and now identified in multiple other tumor types. 128, 129, 131–133 Many TRKA inhibitors have activity against two homologous RTKs, TRKB (NTKR2) and TRKC (NTRK3). These genes are also involved in gene fusions across multiple cancer types, perhaps broadening the appeal of these pan-TRK inhibitors.…”

Section: Ros1 Ret and Ntrk1 Positive Nsclcmentioning

confidence: 99%

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Morgensztern

Campo

Dahlberg

et al. 2015

Journal of Thoracic Oncology

122

103

View full text Add to dashboard Cite

There have been significant advances in the understanding of the biology and treatment of non-small cell lung cancer (NSCLC) over the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC (Table 1). We are beginning to understand the mechanisms of acquired resistance following exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies and immunotherapy.

show abstract

Molecular Biology of Thyroid Cancer

Chien

Koeffler

2011

Thyroid Cancer

View full text Add to dashboard Cite

Molecular rearrangements in papillary thyroid carcinomas

Cited by 18 publications

References 71 publications

Association Study of FOS-Like Antigen-2 Promoter Polymorphisms With Papillary Thyroid Cancer in Korean Population

Association Study of FOS-Like Antigen-2 Promoter Polymorphisms With Papillary Thyroid Cancer in Korean Population

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Molecular Biology of Thyroid Cancer

Contact Info

Product

Resources

About